Do you want to read an article? Please log in or register.
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Leukemia
Related content
Lymphoma
The CAR T Cell Story
healthbook TIMES Oncology Hematology
Russkamp N., Zenz T.
doi: 10.36000/hbT.OH.2019.01.001
Lymphoma
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
N Engl J Med.
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH
doi: 10.1056/NEJMoa1708566.
Lung, Respiratory and Thoracic CancerLeukemiaLymphoma
Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
J Thorac Oncol.
Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS
doi: 10.1016/j.jtho.2017.10.001.
RECOMMENDED
Leukemia
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
★ 2
Recommended by
Alexander Meisel, Faculty Member
Lancet Haematol.
Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS
doi: 10.1016/S2352-3026(20)30277-5.
Leukemia
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
J Clin Oncol.
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG
doi: 10.1200/JCO.2017.72.8519.
Leukemia
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
J Clin Oncol.
Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL
doi: 10.1200/JCO.19.03237.
COMMENTED
Lymphoma
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1056/NEJMoa1914347.
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Lymphoma
Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19
Clin Cancer Res.
Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV
doi: 10.1158/1078-0432.CCR-19-1337.